Stock Yards Bank & Trust Co. Sells 3,764 Shares of Zoetis Inc. $ZTS

Stock Yards Bank & Trust Co. lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 3.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 101,561 shares of the company’s stock after selling 3,764 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Zoetis were worth $15,838,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after acquiring an additional 189,287 shares during the last quarter. Polen Capital Management LLC grew its position in Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares during the last quarter. Northern Trust Corp grew its position in Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after acquiring an additional 78,508 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after acquiring an additional 109,791 shares during the last quarter. Finally, Brown Advisory Inc. grew its holdings in shares of Zoetis by 7.6% during the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after purchasing an additional 312,746 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $146.45 on Friday. The business’s 50 day simple moving average is $149.79 and its 200 day simple moving average is $155.14. Zoetis Inc. has a one year low of $139.34 and a one year high of $196.55. The stock has a market capitalization of $64.91 billion, a PE ratio of 25.21, a PEG ratio of 2.35 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the prior year, the business posted $1.56 earnings per share. The firm’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ZTS shares. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and reduced their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Finally, Piper Sandler boosted their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Five analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.